- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04325386
Clozapine CHAMPION-ECHO Educational Study to Improve Clozapine Use. (CHAMPION)
Clozapine CHAMPION-ECHO (Center for Help and Assistance for Maryland Prescribers- Improving Outcomes Network Using Extension for Community Healthcare Outcomes); Randomized Educational Study to Improve Clozapine Prescribing Through a Project ECHO Model
In a randomized controlled design with approximately 26 biweekly sessions over 12 months, the investigators propose to test the effectiveness of an ECHO-based intervention for improving the use of clozapine in people eligible for clozapine. The sessions will include: 1) active dissemination of knowledge and information by an expert "hub" followed by 2) clozapine case presentations and vignettes submitted by the "spokes".
This intervention, Clozapine CHAMPION-ECHO (Center for Help and Assistance for Maryland Prescribers- Improving Outcomes Network using Extension for Community Healthcare Outcomes, will be referred to as "CHAMPION" throughout.. To minimize ANC monitoring barriers and maximize recruitment, the investigators will provide Food and Drug Administration (FDA)-cleared ANC point of care (POC) monitoring devices to all study sites, including those in the control condition. The investigators will enroll at least 300 prescribers and additional clinical team members (up to 300) from 60 outpatient mental health clinics (OMHCs) and other treatment sites; approximately half the OHMCs will be randomized to CHAMPION and half randomized to enhanced treatment as usual (ETAU).
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Maryland
-
Catonsville, Maryland, United States, 21228
- Maryland Psychiatric Research Center (MPRC) Treatment Research Program (TRP)
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Located at a site in the State of Maryland with at least 3 prescribers at the site.
- Prescribers/clinical team should be licensed in the State of Maryland and have prescribed antipsychotics previously.
- Between the ages of 22 and 85 years old
- Willing to participate in pre- and post-testing
- Willing to agree to try to participate in the CHAMPION sessions
Exclusion Criteria:
- Not willing to participate in CHAMPION Sessions
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Education sessions
Project ECHO (Extension for Community Healthcare Outcomes) based intervention sessions for improving the use of clozapine in people with treatment-resistant schizophrenia.
The sessions will include: 1) active dissemination of knowledge and information by an expert followed by 2) clozapine case presentations and vignettes.
|
Project ECHO (Extension for Community Healthcare Outcomes) based intervention sessions for improving the use of clozapine in people with treatment-resistant schizophrenia.
The sessions will include: 1) active dissemination of knowledge and information by an expert followed by 2) clozapine case presentations and vignettes.
|
Placebo Comparator: No education sessions
|
No Education Session
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
change in clozapine prescriptions using Medicaid claims data
Time Frame: Baseline and endpoint changes after 12 month intervention
|
The data outcome is new clozapine prescriptions by provider based on a variable linking provider ID to clozapine prescriptions.
The outcome is the increase in the proportion of patients treated with clozapine for those in the care of prescribers randomized to the CHAMPION relative to the ETAU condition.
|
Baseline and endpoint changes after 12 month intervention
|
Change in prescriber knowledge of clozapine use
Time Frame: Baseline and endpoint changes after 12 month intervention
|
A 52 item Multiple Choice Questionnaire will be used to assess knowledge.
The knowledge-based test questions will consist of 2 questions per 26 topic areas and will conform to best practices and guidelines for design of the questions.
The total mean score will range from 0-52.
The questions were developed and validated by the team.
|
Baseline and endpoint changes after 12 month intervention
|
Change in self-reported competence for clozapine use
Time Frame: Baseline and endpoint changes after 12 month intervention
|
We will use a mean score on a Visual Analog Scale (VAS) (0-100 mm).
We will have one for overall competence and then one for each of the 26 topic areas.
Overall, self report scores and the global self report scores will be used.
|
Baseline and endpoint changes after 12 month intervention
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- HP-00087399
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Schizophrenia Schizoaffective
-
Teva Branded Pharmaceutical Products R&D, Inc.RecruitingSchizophrenia, Schizoaffective DisorderUnited States
-
Hoffmann-La RocheTerminatedSchizophrenia, Schizoaffective DisorderUnited States, Spain, Japan, Ukraine
-
Solvay PharmaceuticalsWyeth is now a wholly owned subsidiary of Pfizer; H. Lundbeck A/SCompletedSchizophrenia and Schizoaffective DisorderHungary, United States, Argentina, Canada, Czech Republic, Estonia, France, Latvia, Lithuania
-
Central Institute of Mental Health, MannheimCompletedSchizophrenia, Schizoaffective DisorderGermany
-
Hoffmann-La RocheCompletedSchizophrenia, Schizoaffective DisorderUnited States, Japan, Ukraine, Russian Federation
-
AmgenCompletedSchizophrenia or Schizoaffective DisorderUnited States
-
AmgenCompletedSchizophrenia or Schizoaffective DisorderUnited States
-
Otsuka Pharmaceutical Development & Commercialization...Otsuka America PharmaceuticalCompletedSchizophrenia and Schizoaffective Disorder
-
University of Sao PauloUnknownSchizophrenia or Schizoaffective DisorderBrazil
-
Centre for Addiction and Mental HealthOntario Ministry of Health and Long Term CareRecruitingSchizophrenia, Schizoaffective DisorderCanada
Clinical Trials on Education Sessions
-
The University of Hong KongThe Hong Kong Jockey Club Charities Trust; Hong Kong Island Women AssociationUnknownPhysical Activity | Well-being | Healthy Diet | FamilyHong Kong
-
University of NancyIVRSP: Institut Virtuel de Recherche en Santé PubliqueCompleted
-
The Hospital for Sick ChildrenCompleted
-
Kantonsspital Winterthur KSWUnknownCovid-19 (New Coronavirus) InfectionSwitzerland
-
Hamilton Health Sciences CorporationMcMaster UniversityCompleted
-
Northwestern UniversityNational Heart, Lung, and Blood Institute (NHLBI)CompletedCardiovascular Diseases | Peripheral Vascular DiseasesUnited States
-
Memphis VA Medical CenterU.S. Army Medical Research and Development CommandCompletedCoping Skills | Military Personnel | SpousesUnited States
-
Virginia Commonwealth UniversityNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); Children...CompletedType 1 DiabetesUnited States
-
Maureen LyonNational Institute of Mental Health (NIMH)CompletedHIV InfectionsUnited States
-
Mayo ClinicNational Institute on Minority Health and Health Disparities (NIMHD)Active, not recruiting